Welcome to our dedicated page for Voyager Therapeutics news (Ticker: VYGR), a resource for investors and traders seeking the latest updates and insights on Voyager Therapeutics stock.
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company focused on leveraging genetics to treat neurological diseases, and its news flow reflects progress across a multi-modality pipeline. Press releases frequently highlight updates in Alzheimer’s disease programs, including the anti-tau antibody VY7523 and the tau silencing gene therapy VY1706, as well as broader work in Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and other central nervous system conditions.
News items cover clinical and preclinical data presentations at scientific meetings such as the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) and the American Society of Gene & Cell Therapy (ASGCT) annual meeting. Voyager reports new non-human primate and murine data, details on tau and amyloid targeting strategies, and advances in its TRACER™ AAV capsid discovery platform and next-generation capsids designed for blood-brain barrier penetration and immune evasion.
Investors and followers of VYGR can also expect regular financial and operating updates, typically furnished via Form 8-K, that summarize quarterly collaboration revenue, research and development spending, and cash position, along with commentary on cash runway and partnered program milestones. Additional news addresses collaborations and partnerships, including agreements with Neurocrine Biosciences, Novartis Pharma AG, Alexion, AstraZeneca Rare Disease, and a small molecule collaboration and option agreement with Transition Bio targeting TDP-43 in ALS and frontotemporal dementia.
This news page aggregates Voyager’s corporate announcements, scientific data disclosures, partnership updates, and financial reports, providing a centralized view of developments that may influence the company’s therapeutic pipeline and platform evolution. Readers interested in VYGR stock and the company’s role in genetic medicines for neurological disease can use this feed to follow key milestones and scientific progress over time.
Voyager Therapeutics (Nasdaq: VYGR) has announced the selection of a third gene therapy development candidate in collaboration with Neurocrine Biosciences. This candidate, targeting an undisclosed neurological disease, utilizes Voyager's TRACER™ capsid discovery platform for intravenous administration and blood-brain barrier penetration.
The selection triggers a $3 million milestone payment to Voyager, expected in Q4 2024. This follows previous nominations for Friedreich's ataxia and GBA1 Parkinson's disease. Voyager is eligible for additional development and commercialization milestone payments, plus royalties on potential future sales.
The collaboration, established in 2023, covers multiple neurological programs. For each undisclosed program, Voyager can receive up to $175 million in development milestones, commercial milestone payments, and tiered royalties on global net sales.
Voyager Therapeutics (Nasdaq: VYGR) has announced a new license agreement with Novartis AG (NYSE: NVS) for a novel capsid from Voyager's TRACER™ capsid discovery platform. The capsid will be used in a gene therapy program targeting an undisclosed rare neurologic disease. This agreement expands Voyager's partnered portfolio of TRACER-enabled gene therapies to 14 programs.
Key financial terms include:
- $15 million upfront payment to Voyager
- Up to $305 million in potential milestone payments
- Tiered mid- to high-single digit royalties on potential products
This marks the fifth gene therapy program in collaboration with Novartis, including Huntington's disease, spinal muscular atrophy, and three undisclosed indications.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has granted inducement awards to a new employee. The awards, approved by the Compensation Committee under Nasdaq Rule 5635(c)(4), include:
1. A non-qualified stock option for 40,000 shares of common stock, effective August 28, 2024, with a ten-year term and an exercise price of $6.49 per share. It vests over four years: 25% after one year, then 75% monthly over three years.
2. Restricted stock units for 20,000 shares, effective October 1, 2024, vesting annually in equal installments over three years.
Both awards are subject to continued employment and specific award agreements.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in two upcoming investor conferences in September 2024:
- The Wells Fargo 2024 Healthcare Conference in Boston, with a fireside chat on September 5 at 1:30 p.m. ET
- The Baird 2024 Global Healthcare Conference in New York City, featuring a fireside chat on September 11 at 1:25 p.m. ET
Webcasts of the presentations will be available on the Investors section of Voyager's website and archived for at least 30 days. This announcement highlights Voyager's engagement with investors and its commitment to sharing updates on its progress in the field of neurogenetic medicine.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase. The company will engage in a fireside chat on August 14, 2024, at 9:30 a.m. ET.
Investors and interested parties can access a webcast of the presentation through the Investors section of Voyager's website at ir.voyagertherapeutics.com. For those unable to attend live, a replay of the webcast will be available on the company's website for a minimum of 30 days following the event.
Voyager Therapeutics (Nasdaq: VYGR) reported its Q2 2024 financial results and operational progress. Key highlights include:
1. Initiated Phase 1a single ascending dose trial of anti-tau antibody VY7523 for Alzheimer's disease, with top-line data expected in H1 2025.
2. Advanced three CNS gene therapy programs towards INDs in 2025.
3. Appointed Nathan Jorgensen, Ph.D., as CFO.
4. Strong cash position of $371 million as of June 30, 2024, providing runway into 2027.
5. Q2 2024 collaboration revenue increased to $29.6 million, up from $4.9 million in Q2 2023.
6. Net loss decreased to $10.1 million in Q2 2024, compared to $22.2 million in Q2 2023.
7. R&D expenses increased to $34.5 million in Q2 2024, up from $22.0 million in Q2 2023.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its upcoming second quarter 2024 financial results release and conference call. The company will report its Q2 2024 financial and operating results after market close on Tuesday, August 6, 2024. Following this, Voyager will host a conference call and webcast at 4:30 p.m. ET.
Interested participants can register for the telephone conference in advance through a provided link. A live webcast will be available on the Investors section of Voyager's website, with a replay accessible for at least 30 days after the call.
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focusing on neurogenetic medicines, has granted inducement awards to new employee Eric Hall, Ph.D., M.B.A. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), include:
1. A non-qualified stock option for 36,000 shares, effective July 22, 2024, with a ten-year term and an exercise price of $8.77 per share. It vests over four years: 25% after one year, then 75% monthly over three years.
2. Restricted stock units for 18,000 shares, effective October 1, 2024, vesting annually in equal installments over three years.
Both awards are subject to Dr. Hall's continued employment with Voyager and the terms of their respective award agreements.
Voyager Therapeutics (Nasdaq: VYGR) announced the induction of Nathan Jorgensen, Ph.D., M.B.A., into their team with a notable employment agreement. This agreement includes a non-qualified stock option for 200,000 shares and restricted stock units (RSUs) for 80,000 shares as part of the inducement process, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4). The stock option, effective July 8, 2024, carries an exercise price of $7.79 per share, matching the closing price on the effective date. The options vest over four years, with 25% vesting on the first anniversary and the remaining 75% in equal monthly installments over the next three years. The RSUs will vest annually in equal installments over three years starting October 1, 2024. These equity awards are contingent upon Dr. Jorgensen's ongoing employment with Voyager and are subject to specific award agreements.
Voyager Therapeutics (Nasdaq: VYGR), a biotech company specializing in neurogenetic medicines, will participate in two virtual investor conferences in June 2024.
The company will present at the TD Cowen Genetic Medicines & RNA Summit on June 20 at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27 at 7:00 a.m. ET. Both presentations will be webcasted and available on Voyager’s investor website, with replays accessible for at least 30 days.
FAQ
What is the current stock price of Voyager Therapeutics (VYGR)?
What is the market cap of Voyager Therapeutics (VYGR)?
